报价延迟最少15分钟:2026/07/06 16:56 EDT
盘后时段
|
||||
|
6.01 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
6.01
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.25/-1.75
|
|
企业价值
94.74M
|
| 资产负债 |
|
每股账面净值
-1.47
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
200.00K
|
|
每股收益
0.06
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercializationof dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46. |
